Development of Islet-Targeted Drug Delivery Strategies in T1D

The JDRF Cures Program aims to halt the progression of T1D and ultimately achieve a cure through the development of disease-modifying therapies (small molecules and/or biologics) that promote the survival, function, and regeneration of endogenous insulin-producing beta cells. In addition to traditional drug conjugate approaches, JDRF is also interested in gene delivery approaches via viral (e.g. AAVs, etc.) or non-viral (e.g. biomaterial scaffolds, etc.) platforms. The utility of newer generations of viruses with beta cell specific trophism are of particular interest.

Respondents to this RFA will possess the skills needed to identify and validate islet cell specific addresses and develop reagents for those addresses.

Funding: no fixed limit 

Duration: 3 years (applications with increased scope may be considered) 

Research Authority due date: 10.8.22

LOI (required) due date: 17.8.22

Full proposal due date: 5.10.22